Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 21
November 2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc
GSK publishes provisional dividend dates
GSK
announces the following dividend dates
for 2017 and 2018:
|
|
Results announcement date
|
Ex-dividend
date*
|
Record date
|
Last date for DRIP elections
|
Payment date
|
|
Q4 2017
|
7
February
2018
|
22
February 2018
|
23
February 2018
|
20
March 2018
|
12
April 2018
|
|
Q1 2018
|
25
April
2018
|
10 May
2018
|
11 May
2018
|
21 June
2018
|
12 July
2018
|
|
Q2 2018
|
25
July
2018
|
9
August
2018
|
10
August 2018
|
20
September
2018
|
11
October
2018
|
|
Q3 2018
|
31
October
2018
|
15
November 2018
|
16
November
2018
|
17
December
2018
|
10
January 2019
|
These
dates are indicative and may be subject to
change.
V A Whyte
Company Secretary
21 November 2017
*In
accordance with the Securities and Exchange Commission guidance in
respect of the standard settlement cycle on securities transactions
changing from T+3 to T+2 effective from 5 September 2017, the
ex-dividend date for ADR holders and ordinary shareholders is now
the same date.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
21, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|